- CEO
- Rahul Franklin Guha
- Full Time Employees
- 2,092
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- D/37-3, TTC Industrial Area Navi Mumbai MA India 400703
- IPO Date
- May 9, 2016
- Business
- Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, hospitals and clinics primarily in India. The company operates through diagnostic testing services, imaging services and other segments; offers more than 900 tests and 288 profiles including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility and infectious disease tests; provides preventive wellness packages under the Aarogyam brand such as Aarogyam and Jaanch; sells glucometers and glucostrips under the Sugarscan brand, consumables and radiopharmaceutical products; conducts cancer diagnosis through its Nueclear brand and water testing through Whaters; and delivers imaging services including PET-CT scans, nuclear scanning, MRI, CT scans and ultrasonography via subsidiary Nueclear Healthcare Limited and recent 51% stake in Pulse Hitech Health Services LLP. Thyrocare Technologies maintains a centralized processing laboratory and regional facilities in Navi Mumbai with air-cargo logistics supporting a franchise network exceeding 10,100 active centers nationwide and international expansion in markets like Tanzania. Founded in 1995 and incorporated in 2000, the company is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited. Recent developments include the acquisition of Vimta Labs' diagnostic and pathological services business in 2024 to bolster presence in South India and Telangana; a 2:1 bonus issue announced in October 2025 with record date November 28, 2025; franchise-led growth with pathology volumes up 21% year-on-year and bundled packages rising 19-31%; full NABL accreditation across all laboratories; and a strategic shift in FY24 toward cost streamlining, pay-for-performance incentives and volume-led expansion driving revenue growth of 24.5% in franchise pathology.